share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股sec公告 ·  04/22 16:23
Moomoo AI 已提取核心信息
On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.
On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.
2024年4月17日,生物技术公司Exicure, Inc. 因未提交截至2023年12月31日的10-K表年度报告而收到纳斯达克股票市场的拖欠通知。未能申报导致不遵守纳斯达克上市规则5250(c)(1),该规则要求及时向美国证券交易委员会提交定期财务报告。该公司此前曾获准将拖欠的第三季度10-Q表延长至2024年5月20日,现在还必须在同日之前提交逾期的10-K表才能恢复合规。Exicure的管理层正在积极努力完成10-K表格,并计划尽快提交。该公司已暂停临床和开发活动,目前正在探索提高股东价值的战略替代方案。
2024年4月17日,生物技术公司Exicure, Inc. 因未提交截至2023年12月31日的10-K表年度报告而收到纳斯达克股票市场的拖欠通知。未能申报导致不遵守纳斯达克上市规则5250(c)(1),该规则要求及时向美国证券交易委员会提交定期财务报告。该公司此前曾获准将拖欠的第三季度10-Q表延长至2024年5月20日,现在还必须在同日之前提交逾期的10-K表才能恢复合规。Exicure的管理层正在积极努力完成10-K表格,并计划尽快提交。该公司已暂停临床和开发活动,目前正在探索提高股东价值的战略替代方案。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息